← All trials
NCT01788631
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2013
- Primary completion
- Oct 1, 2016
- Completion date
- Jun 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Medical College of WisconsinCollaborator
- Duke UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- Wayne State UniversityCollaborator
- University of California, San FranciscoCollaborator
- University of CincinnatiCollaborator
- La Jolla Institute for Allergy & ImmunologyCollaborator
- Baylor UniversityCollaborator
- Harvard UniversityCollaborator
- Washington University in St. LouisCollaborator
- University of Illinois at ChicagoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.